<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02560207</url>
  </required_header>
  <id_info>
    <org_study_id>2014/468</org_study_id>
    <nct_id>NCT02560207</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Continuous Versus Intermittent Cefotaxime Infusion on ICU.</brief_title>
  <official_title>Does Continuous Cefotaxime Administration Improve Time to Attainment and Maintenance of Target Drug Levels in Critically Ill Patients?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates target attainment after either intermittent intravenous bolus or
      intravenous continuous infusion of cefotaxime in critically ill patients. Critically ill
      patients will be randomized to intermittent infusion or continuous infusion of cefotaxime.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critically ill patients have other pharmacokinetic/pharmacodynamic profiles than healthy
      volunteers. Suboptimal, both under- and overdosing of antibiotics is an important threat in
      this patient category. Given the time-dependent character of beta-lactam antibiotics
      continuous dosing as opposed to traditional intermittent dosing is likely to render better
      target attainment and maintenance and might improve clinical outcome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cefotaxim serum concentrations</measure>
    <time_frame>40 min, 1 hour, 2, 4, 8, 12 and 24 hours; 36h; 48 h; 60h; 72h; 84h and 96h post administration</time_frame>
    <description>Cefotaxime serum concentrations, total and unbound, will be determined. The Pharmacokinetic/Pharmacodynamic (PK/PD) target of total serum concentration of 4 times above minimal inhibitory concentration (MIC) ascertains that the unbound drug serum concentration will be above the MIC value of 1 mg/mL, which is determined to be the minimum target.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of cefotaxim</measure>
    <time_frame>0-96h post administration</time_frame>
    <description>Based on the data from the primary outcome measure a pharmacokinetic model for ICU patients will be developed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Critically Ill</condition>
  <arm_group>
    <arm_group_label>Intermittent cefotaxime</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cefotaxime 1 gram (1000 mg) is to be administered 4 times daily for 4 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous cefotaxime</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After a 1 gram (1000 mg) Cefotaxime loading dose, Cefotaxime 4 gram (4000 mg) is to be administered as a continuous infusion in 24h for 4 days .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefotaxime</intervention_name>
    <description>To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.</description>
    <arm_group_label>Intermittent cefotaxime</arm_group_label>
    <arm_group_label>Continuous cefotaxime</arm_group_label>
    <other_name>Claforan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Admitted to intensive care

          -  Able to give informed consent by themselves or informed consent can be obtained via
             next of kin

          -  Indication for treatment with cefotaxime (as judged by treating physician) in the
             context of our standard treatment protocol of Selective decontamination of the
             digestive tract (SDD).

        Exclusion Criteria:

          -  Renal replacement therapy

          -  Contra-indication for cefotaxime, including known or suspected allergy to cefotaxime

          -  No indication for an arterial line; an arterial line will not be placed solely for the
             purpose of this study; thus, only patients with an indication for an arterial line
             outside this protocol are eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan G Zijlstra, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Critical Care, UMCG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>Prof. dr. J.G. Zijlstra</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cefotaxime</mesh_term>
    <mesh_term>Cefoxitin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

